Open innovation in high-technology companies : Case study of biotechnology and pharmaceutical companies

dc.contributor.authorHeimo, Teppo
dc.contributor.facultyfi=Tekniikan ja innovaatiojohtamisen yksikkö|en=School of Technology and Innovations|-
dc.contributor.organizationfi=Vaasan yliopisto|en=University of Vaasa|
dc.date.accessioned2019-08-14T07:50:23Z
dc.date.accessioned2025-06-25T15:43:23Z
dc.date.available2019-08-14T07:50:23Z
dc.date.issued2019-08-01
dc.description.abstractCompanies innovation process is an important way to both achieve and sustain competitive advantage in today’s business world. The innovation happens in companies within a process consisting from three processes: the front-end innovation process, the new product development process, and commercialization process. The innovation strategy of companies is comprised from different attributes that the company’s emphasis and values in their decision-making process. The theoretical framework of this thesis is built on the principles on open innovation, aggressiveness strategy of the companies, and holistic analytical model developed to evaluate companies’ strategic priorities. The open innovation is scoped by selected strategic attributes in the companies, from which the overall innovation strategy of the company is formed. This study tries to analytically model the open innovation strategy of the case companies within biotechnology and pharmaceutical industries. This study uses several critical factors index-based methods to evaluate the past experiences and future expectations of the companies’ top management personnel around the open innovation. In addition, an analytical hierarchy process method is used to specify and evaluate the case companies’ overall innovation strategy around open innovation parameters. This study evaluates the different innovation strategy types used in high technology companies. This study was able to quantitatively determine the innovation strategy types of the case companies using the innovation strategy index method, which was originally derived from manufacturing strategy index method. However, no correlation around the resource allocation index and innovation strategy index was not found.-
dc.format.bitstreamtrue
dc.format.extent115-
dc.identifier.olddbid8446
dc.identifier.oldhandle10024/8200
dc.identifier.urihttps://osuva.uwasa.fi/handle/11111/7342
dc.identifier.urnURN:NBN:fi-fe2019080223411-
dc.language.isoeng-
dc.rightsCC BY 4.0-
dc.rights.accessrightsfi=Opinnäytetyö kokotekstinä PDF-muodossa.|en=Thesis fulltext in PDF format.|sv=Lärdomsprov tillgängligt som fulltext i PDF-format|-
dc.source.identifierhttps://osuva.uwasa.fi/handle/10024/8200
dc.subjectinnovation, open innovation, front-end innovation process, analytical hierarchy process, resource allocation, performance measurement-
dc.subject.degreeprogrammeMaster's Programme in Industrial Management-
dc.subject.disciplinefi=Tuotantotalous|en=Industrial Management|-
dc.titleOpen innovation in high-technology companies : Case study of biotechnology and pharmaceutical companies-
dc.type.ontasotfi=Pro gradu -tutkielma|en=Master's thesis|sv=Pro gradu -avhandling|-

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
UniVaasa_2019_Heimo_Teppo.pdf
Size:
37.33 MB
Format:
Adobe Portable Document Format
Description:
Pro gradu -tutkielma